These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 20847637)

  • 1. Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease.
    Llano DA; Laforet G; Devanarayan V;
    Alzheimer Dis Assoc Disord; 2011; 25(1):73-84. PubMed ID: 20847637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
    Podhorna J; Krahnke T; Shear M; Harrison JE;
    Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI.
    Skinner J; Carvalho JO; Potter GG; Thames A; Zelinski E; Crane PK; Gibbons LE;
    Brain Imaging Behav; 2012 Dec; 6(4):489-501. PubMed ID: 22614326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation study of the Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog) for the Portuguese patients with mild cognitive impairment and Alzheimer's disease.
    Nogueira J; Freitas S; Duro D; Almeida J; Santana I
    Clin Neuropsychol; 2018; 32(sup1):46-59. PubMed ID: 29566598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examining the reliability of ADAS-Cog change scores.
    Grochowalski JH; Liu Y; Siedlecki KL
    Neuropsychol Dev Cogn B Aging Neuropsychol Cogn; 2016 Sep; 23(5):513-29. PubMed ID: 26708116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers for predicting cognitive decline in those with normal cognition.
    Steenland K; Zhao L; Goldstein F; Cellar J; Lah J
    J Alzheimers Dis; 2014; 40(3):587-94. PubMed ID: 24496071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a calibrated (18)F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment.
    Herholz K; Westwood S; Haense C; Dunn G
    J Nucl Med; 2011 Aug; 52(8):1218-26. PubMed ID: 21764801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials.
    Raghavan N; Samtani MN; Farnum M; Yang E; Novak G; Grundman M; Narayan V; DiBernardo A;
    Alzheimers Dement; 2013 Feb; 9(1 Suppl):S21-31. PubMed ID: 23127469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian estimation for the accuracy of three neuropsychological tests in detecting Alzheimer's disease and mild cognitive impairment: a retrospective analysis of the ADNI database.
    Wang X; Li F; Tian J; Gao Q; Zhu H
    Eur J Med Res; 2023 Oct; 28(1):427. PubMed ID: 37821912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI).
    Crane PK; Carle A; Gibbons LE; Insel P; Mackin RS; Gross A; Jones RN; Mukherjee S; Curtis SM; Harvey D; Weiner M; Mungas D;
    Brain Imaging Behav; 2012 Dec; 6(4):502-16. PubMed ID: 22782295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease.
    Sano M; Raman R; Emond J; Thomas RG; Petersen R; Schneider LS; Aisen PS
    Alzheimer Dis Assoc Disord; 2011; 25(2):122-7. PubMed ID: 20921876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of Alzheimer disease assessment scale-cognitive part in predicting progress for amnestic mild cognitive impairment to Alzheimer disease.
    Rozzini L; Vicini Chilovi B; Bertoletti E; Conti M; Delrio I; Trabucchi M; Padovani A
    J Geriatr Psychiatry Neurol; 2008 Dec; 21(4):261-7. PubMed ID: 19017783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The characteristics of patients with uncertain/mild cognitive impairment on the Alzheimer disease assessment scale-cognitive subscale.
    Pyo G; Elble RJ; Ala T; Markwell SJ
    Alzheimer Dis Assoc Disord; 2006; 20(1):16-22. PubMed ID: 16493231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment.
    Lorenzi M; Donohue M; Paternicò D; Scarpazza C; Ostrowitzki S; Blin O; Irving E; Frisoni GB;
    Neurobiol Aging; 2010 Aug; 31(8):1443-51, 1451.e1. PubMed ID: 20541287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
    Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
    Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Validation of the Hungarian version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild cognitive impairment].
    Papp E; Pákáski M; Drótos G; Kálmán J
    Psychiatr Hung; 2012; 27(6):426-34. PubMed ID: 23429337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does serum uric acid act as a modulator of cerebrospinal fluid Alzheimer's disease biomarker related cognitive decline?
    Ye BS; Lee WW; Ham JH; Lee JJ; Lee PH; Sohn YH;
    Eur J Neurol; 2016 May; 23(5):948-57. PubMed ID: 26917248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The validity and reliability of the Turkish version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects.
    Mavioglu H; Gedizlioglu M; Akyel S; Aslaner T; Eser E
    Int J Geriatr Psychiatry; 2006 Mar; 21(3):259-65. PubMed ID: 16477580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
    Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
    Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.